γδ T细胞在结核病免疫治疗的研究及其应用前景  

γδ T cells in tuberculosis immunotherapy and future prospects

作　　者：付亮 梁娟 张国良 吴扬哲 邓国防 FU Liang;LIANG Juan;ZHANG Guo-liang;WU Yang-zhe;DENG Guo-fang(The Second Department of Lung,Shenzhen Third People’s Hospital,Southern University of Science and Technology,Shenzhen 518000,China)

机构地区：[1]南方科技大学附属深圳市第三人民医院肺二科,518000 [2]南方科技大学研究所,518000 [3]暨南大学生物医学转化研究院

出　　处：《中国防痨杂志》2019年第6期695-699,共5页Chinese Journal of Antituberculosis

基　　金：2018年度深圳市卫生系统科研项目(SZLY2018017).

摘　　要：传统抗结核药物一般直接作用于结核分枝杆菌,在遏制结核病流行方面贡献巨大,但目前遇到了诸多障碍,亟需新的治疗策略。近年来“宿主靶向治疗”开始兴起,并显示有良好疗效,包括老药新用、细胞免疫治疗等;其中γδT细胞的功能和作用日渐受到免疫学家和临床医师的重视。γδT细胞是一类不同于αβT细胞的T细胞亚群,其免疫治疗的安全性和有效性已经在抗肿瘤治疗的临床试验中得到确认。目前,动物实验及人类观察性研究已经证明γδT细胞在调节结核病患者免疫反应方面有重要作用。笔者对宿主靶向治疗,尤其是γδT细胞免疫治疗的现状,以及相关的基础研究和临床前研究进行综述,并提出进一步开发其抗结核治疗潜力的可能性。Traditional anti-tuberculosis drugs, directly targeting on the Mycobacterium tuberculosis, have played important roles on controlling tuberculosis. However, new strategies for treatment are needed to solve the remaining problems. In recent years,“host-directed therapy”,including new use of old drugs and cell immunotherapies, has been reported to have exciting efficacy. The γδ T cell immunotherapy attracted especial attention by immunologists and clinicians. The γδ T cells are a subset of T cells, quite different from αβ T cells. The safety and efficacy of γδ T cell immunotherapy for cancer treatment have been confirmed in clinical trials. At present, studies on animal and human with tuberculosis have demonstrated that γδ T cells play important roles in immune response against tuberculosis. This review introduces current implications of host-targeted therapy, especially γδ T cell immunotherapy in tuberculosis treatment, and recent progresses of the basic research and preclinical studies on this new therapy, and also proposes potential possibilities in anti-tuberculosis treatment.

关 键 词：结核 T淋巴细胞亚群 分子靶向治疗 免疫疗法 

分 类 号：R52[医药卫生—内科学]